Federica Turati1, Cristina Bosetti2, Jerry Polesel3, Diego Serraino4, Maurizio Montella5, Massimo Libra6, Gaetano Facchini7, Monica Ferraroni8, Alessandra Tavani9, Carlo La Vecchia10, Eva Negri11. 1. Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Via A. Vanzetti, 5, 20133 Milan, Italy; Unit of Medical Statistics, Biometry and Bioinformatics, Fondazione IRCCS Istituto Nazionale Tumori, di Milano, via G. Venezian 1, 20133 Milan, Italy. Electronic address: federica.turati@unimi.it. 2. Department of Epidemiology, IRCCS-Istituto di Ricerche Farmacologiche "Mario Negri", via G. La Masa 19, 20156 Milan, Italy. Electronic address: cristina.bosetti@marionegri.it. 3. Unit of Cancer Epidemiology, CRO Aviano National Cancer Institute, IRCCS, via F. Gallini 2, 33080 Aviano, Italy. Electronic address: polesel@cro.it. 4. Unit of Cancer Epidemiology, CRO Aviano National Cancer Institute, IRCCS, via F. Gallini 2, 33080 Aviano, Italy. Electronic address: serrainod@cro.it. 5. Unit of Epidemiology, Istituto Tumori "Fondazione Pascale IRCCS", Via M. Semmola 1, 80131 Naples, Italy. Electronic address: m.montella@istitutotumori.na.it. 6. Department of Biomedical Sciences, Università di Catania, Via Androne 83, 95124 Catania, Italy. Electronic address: m.libra@unict.it. 7. Division of Medical Oncology, Department of Uro-ginecological Oncology, Istituto Tumori "Fondazione Pascale IRCCS", Via M. Semmola 1, 80131, Naples Italy. Electronic address: g.facchini@istitutotumori.na.it. 8. Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Via A. Vanzetti, 5, 20133 Milan, Italy. Electronic address: monica.ferraroni@unimi.it. 9. Department of Epidemiology, IRCCS-Istituto di Ricerche Farmacologiche "Mario Negri", via G. La Masa 19, 20156 Milan, Italy. Electronic address: alessandra.tavani@marionegri.it. 10. Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Via A. Vanzetti, 5, 20133 Milan, Italy. Electronic address: carlo.lavecchia@unimi.it. 11. Department of Biomedical and Clinical Sciences, Università degli Studi di Milano, Via G. B. Grassi 74, 20157 Milan, Italy. Electronic address: eva.negri@unimi.it.
Abstract
BACKGROUND: A family history of bladder cancer has been associated with the risk of bladder cancer, but quantification of the excess risk in different populations is still a relevant issue. Further, the role of a family history of other cancers on the risk of bladder cancer remains unclear. METHODS: We analyzed data from an Italian case-control study, including 690 bladder cancer cases and 665 hospital controls. Odds ratios (ORs) were estimated through unconditional logistic regression models, adjusted for sex, age, study center, year of interview and further for education, smoking and sibling's number. RESULTS: The OR for family history of bladder cancer was 2.13 (95% confidence intervals (95%CIs) 1.02-4.49) from the model with partial adjustment, and 1.99 (95%CI 0.91-4.32) after additional adjustment for smoking and siblings' number, based on 23 cases (3.3%) and 11 controls (1.7%) with a family history of bladder cancer. The fully adjusted OR was 3.77 when the relative was diagnosed at age below 65years. Smokers with a family history of bladder cancer had a four-fold increased risk compared to non-smokers without a family history. Bladder cancer risk was significantly increased among subjects with a family history of hemolymphopoietic cancers (OR=2.97, 95%CI 1.35-6.55). Family history of cancer at other sites showed no significant association with bladder cancer risk. CONCLUSION: This study confirms an approximately two-fold increased risk of bladder cancer for family history of bladder cancer, and indicates a possible familial clustering of bladder cancer with cancers of the hemolymphopoietic system.
BACKGROUND: A family history of bladder cancer has been associated with the risk of bladder cancer, but quantification of the excess risk in different populations is still a relevant issue. Further, the role of a family history of other cancers on the risk of bladder cancer remains unclear. METHODS: We analyzed data from an Italian case-control study, including 690 bladder cancer cases and 665 hospital controls. Odds ratios (ORs) were estimated through unconditional logistic regression models, adjusted for sex, age, study center, year of interview and further for education, smoking and sibling's number. RESULTS: The OR for family history of bladder cancer was 2.13 (95% confidence intervals (95%CIs) 1.02-4.49) from the model with partial adjustment, and 1.99 (95%CI 0.91-4.32) after additional adjustment for smoking and siblings' number, based on 23 cases (3.3%) and 11 controls (1.7%) with a family history of bladder cancer. The fully adjusted OR was 3.77 when the relative was diagnosed at age below 65years. Smokers with a family history of bladder cancer had a four-fold increased risk compared to non-smokers without a family history. Bladder cancer risk was significantly increased among subjects with a family history of hemolymphopoietic cancers (OR=2.97, 95%CI 1.35-6.55). Family history of cancer at other sites showed no significant association with bladder cancer risk. CONCLUSION: This study confirms an approximately two-fold increased risk of bladder cancer for family history of bladder cancer, and indicates a possible familial clustering of bladder cancer with cancers of the hemolymphopoietic system.
Authors: Sanaz Ghafouri; Aaron Burkenroad; Morgan Pantuck; Bara Almomani; Dimitris Stefanoudakis; John Shen; Alexandra Drakaki Journal: World J Urol Date: 2020-05-02 Impact factor: 4.226
Authors: Aram Vosoughi; Tuo Zhang; Kyrillus S Shohdy; Panagiotis J Vlachostergios; David C Wilkes; Bhavneet Bhinder; Scott T Tagawa; David M Nanus; Ana M Molina; Himisha Beltran; Cora N Sternberg; Samaneh Motanagh; Brian D Robinson; Jenny Xiang; Xiao Fan; Wendy K Chung; Mark A Rubin; Olivier Elemento; Andrea Sboner; Juan Miguel Mosquera; Bishoy M Faltas Journal: Nat Commun Date: 2020-12-03 Impact factor: 14.919